The use of 68Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities

The use of ⁶⁸Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities

Future Sci OA. 2021 Apr 7;7(6):FSO705. doi: 10.2144/fsoa-2021-0035.

¹ Medical Oncology Complex Unit, ASL Napoli 2 Nord 'Santa Maria delle Grazie' Hospital, Pozzuoli, Italy.
² Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Napoli, Campania, Italy.
³ Unit of Infectious Diseases, Department of Clinical & Experimental Medicine, University of Messina, Messina, Italy.
⁴ Oncology Unit, SG Moscati Hospital, Taranto, Italy.
⁵ Andrology & Urogynecological clinic, Santa Maria Terni Hospital, Terni, University of Perugia, Perugia, Italy.
⁶ Division of Urology, European Institute of Oncology, Milan, 20141, Italy.
⁷ Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy.
⁸ Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, Department of Oncology & Hematology, AOU Federico II of Naples, Naples, 80131, Italy.
⁹ National Reference Center for Environmental Health, Zoo-prophylactic Institute of Southern Italy, Portici, 80055, Italy.

No abstract available

Keywords: PSMA PET; nuclear medicine; prostate cancer.